New findings by the scientists from the Women’s Health Initiative, published in Cancer Epidemiology, Biomarkers & Prevention, confirm the risk of breast cancer among women who are obese and not physically active, and suggest additional mechanisms beyond estrogen.
“Breast cancer is not just one disease. It is a complex combination of many diseases,” Amanda Phipps, PhD, a postdoctoral fellow at the Fred Hutchinson Cancer Research Center, stated in a press release. “The fact that we found an association with triple-negative breast cancer is unique because, biologically, this subtype is different from other breast cancers.”
Epidemiologists have long noted a link between obesity and increased risk of postmenopausal breast cancer, as well as a decreased risk that comes with greater physical activity. A relationship between adipose tissue and estrogen is thought to contribute to this risk.
Phipps and colleagues analyzed data from the 155,723 women enrolled in the Women’s Health Initiative. They assessed levels of baseline body mass index (BMI) and recreational physical activity among the 307 women who had triple-negative breast cancer and the 2,610 women who had estrogen receptor-positive breast cancer.
Results showed that women with the highest BMI had a 35% increased risk of triple-negative breast cancers and a 39% increased risk of estrogen receptor-positive breast cancers. Those who reported high rates of physical activity had a 23% decreased risk of triple-negative breast cancer and a 15% decreased risk of estrogen receptor-positive breast cancer.
“The body of literature, primarily meta-analyses, has shown most of the risk between obesity and breast cancer to be among the estrogen receptor-positive subtypes,” Amy Trentham-Dietz, PhD, an associate professor of population health sciences at the University of Wisconsin and an editorial board member of Cancer Epidemiology, Biomarkers & Prevention, stated. “This paper raises questions about the possible role of growth factors or inflammation, but these will need to be explored with larger patient groups with known breast cancer subtypes, especially triple-negative breast cancers.”
